Pseudotyping Adenoviral Vectors Construction
Numerous biological characteristics of adenoviruses have made them the vehicle of choice for both in vivo and in vitro applications. Although adenovirus gene delivery vectors are valuable in many fields of gene therapy, their broad tropism means that they can't be directed to a specific target cell. Pseudotyping as a general technique describes the use of an exogenous viral envelope glycoprotein to change the tropism of the virus. As a leading expert in gene therapy market, Creative Biolabs provides various pseudotyped adenoviral vector construction services to satisfy clients' requirements through modifying the plasmid encoding the expression of envelope proteins. This enables us to alter the host range and the tissue tropism of adenoviral viral vectors.
Pseudotyping of Adenoviral Vectors
Viral pseudotyping is a strategy to create vectors with new tropism and trafficking properties. Pseudotyping of envelope fusion proteins is a natural adaptive mechanism of viral evolution that has been reported in certain viruses, including adenoviruses. Capsid proteins and envelope glycoproteins take a part in virus attachment and interaction with cellular receptors, deciding cell tropism. Therefore, manipulation of viral surface proteins may improve the transducing ability of these vectors, expanding or limiting their tropism. Furthermore, pseudotyped vectors demonstrate higher transduction titer and efficacy. Pre-existing immunity and diverse tropism restrain the wide use of recombinant adenovirus in gene therapy. These two features can be addressed by modifying immunogenic epitopes of adenovirus capsid, specifically located at hexon.
Figure 1. Strategies for modifying adenoviral vectors.1
The Challenge: The Bottleneck of Wild-Type Adenoviral Vectors
Recombinant adenoviruses, particularly human adenovirus serotype 5 (Ad5), are among the most powerful and widely used gene delivery vehicles due to their high transduction efficiency, massive cloning capacity, and ability to infect both dividing and non-dividing cells. However, transitioning these vectors from in vitro success to in vivo clinical efficacy is severely hindered by two major biological barriers:
Broad Natural Tropism & The "Hepatic Sponge" Effect: Wild-type Ad5 infection is highly dependent on the Coxsackievirus and Adenovirus Receptor (CAR). Unfortunately, many critical target cells (such as hematopoietic stem cells, malignant solid tumors, and mature muscle cells) exhibit low CAR expression. Furthermore, upon systemic intravenous administration, the native Ad5 hexon protein binds with high affinity to blood coagulation Factor X (FX). This interaction rapidly sequesters over 90% of the viral particles into the liver, resulting in severe hepatotoxicity, systemic inflammation, and a drastically reduced effective dose at the intended target site.
The Pre-existing Immunity Hurdle: Epidemiological data indicates that up to 90% of the global adult population harbors pre-existing neutralizing antibodies (nAbs) against common adenovirus serotypes like Ad5. When injected into the bloodstream, these antibodies rapidly neutralize the viral vectors, marking them for clearance by tissue macrophages before they can ever reach their target cells.
Pseudotyping of Adenoviral Vectors at Creative Biolabs
For the purposes of gene therapy or vaccine application, scientists might either want to expand or limit the range of cells susceptible to transduction by a therapeutic vector. Many commonly used gene transfer vectors have been pseudotyped for clinical practices. At Creative Biolabs, we'd like to help customers to develop pseudotyping adenoviral vectors in which the endogenous viral envelope proteins can be replaced by envelope proteins from other viruses or some chimeric proteins. Such chimera is composed of viral protein parts necessary for incorporation into the virion, together with sequences able to interact with specific proteins of hosts.
Recombinant adenoviral vectors show extensive promise as pharmaceutical drugs to treat or prevent a variety of human diseases. However, they hold two main issues of in vivo vector toxicity and specificity. Remarkably, we offer customized viral vector construction services to alter adenoviral vector design and improve delivery capacity, for example, pseudotyping serotype 5 vectors with coat proteins originated from alternative serotypes. The resulting pseudotyped adenoviral vector, that is not prone to neutralization and has high target specificity, theoretically allows for a lower dose in administrated in vivo.
1. Capsid Engineering & Fiber Modification
We redesign adenoviral capsid proteins to:
- Retarget viral entry pathways
- Enable CAR-independent infection
- Enhance receptor-specific binding
2. Cross-Serotype Pseudotyping
We generate chimeric adenoviral vectors by combining:
- Ad5 backbone + alternative serotype fibers
- Hybrid capsids with improved tissue specificity
3. Envelope Glycoprotein Incorporation
We introduce heterologous viral proteins to:
- Expand tropism to non-permissive cells
- Improve viral internalization pathways
4. Immunogenicity Modulation
We engineer capsid epitopes to:
- Reduce neutralizing antibody recognition
- Enable repeated dosing strategies
- Improve in vivo persistence
5. Targeted Ligand Display
We integrate targeting ligands or peptides for:
- Tumor-specific delivery
- Tissue-specific targeting
- Precision gene therapy applications
Expensive Pseudotyping Repertoire – Beyond Traditional Serotypes
We maintain an extensive library of fiber knob variants and chimeric constructs, allowing you to select the optimal pseudotype for your application:
| Pseudotype | Target Receptor | Key Advantages | Ideal Applications |
|---|---|---|---|
| Ad5/35 (chimeric) | CD46 (ubiquitous on human cells) | High transduction of hematopoietic cells, dendritic cells, and multiple myeloma; low anti-Ad35 seroprevalence | HSC gene therapy, leukemia, vaccine delivery |
| Ad5/11 | CD46 + unknown co-receptor | Efficient transduction of human cancer cells and hepatocytes after intravenous delivery; minimal cross-neutralization with Ad5 | Liver-directed gene therapy, oncolytic virotherapy |
| Ad5/48 | Desmoglein-2, CD46 | Excellent for colon carcinoma, lung epithelial cells; extremely low pre-existing immunity | Lung cancer, colorectal cancer, rare disease models |
| Ad5/3 (group B) | Desmoglein-2, integrins | Broad tropism, superior for ovarian cancer, glioblastoma, and stem cells; completely evades Ad5 NAbs | Ovarian cancer, brain tumors, stem cell engineering |
| VSV-G pseudotyped Ad5 | Lipid membrane / ubiquitous | Ultra-broad tropism, high-efficiency transduction of neurons, T cells, and even non-dividing cells; resistant to anti-adenovirus antibodies | Neuroscience, ex vivo T cell engineering, vaccine boost |
| Custom chimeric fibers | User-defined | Precision targeting to specific surface markers | Tumor-specific targeting, cell-type restricted gene editing |
Why Partner with Creative Biolabs?
Why do top-tier academic institutions and leading Biotech companies outsource their most complex viral vector engineering to us?
- Deep Molecular Virology Expertise: We utilize proprietary bacterial homologous recombination technologies optimized for massive DNA fragments. This allows us to achieve complex, multi-site capsid chimerism that standard molecular cloning labs struggle to execute.
- Exclusive Serotype Library: Beyond common serotypes, we possess the complete genomic sequences and rescue technologies for dozens of rare human and non-human primate adenoviruses.
- Guaranteed Delivery: We offer a 100% success guarantee on all vectors that pass our initial feasibility evaluation—if we don't deliver, you don't pay.
- Seamless Downstream Integration: We don't just supply the virus; we provide complementary immunological assays, in vivo efficacy modeling, and toxicology profiling to accelerate your research.
Our End-to-End Workflow
Step 1: Project Design & Target Definition
- Target cell/tissue identification
- Receptor profiling and entry pathway analysis
- Vector backbone selection
Step 2: Pseudotyping Strategy Design
- Capsid modification plan
- Selection of envelope proteins or serotype components
- Tropism optimization strategy
Step 3: Molecular Construction
- Shuttle plasmid design
- Recombinant genome assembly
- Capsid engineering
Step 4: Virus Rescue & Amplification
- Transfection into packaging cells
- Viral rescue and amplification
- Plaque purification
Step 5: Validation & Characterization
- Transduction efficiency testing
- Tropism verification
- Receptor dependency analysis
Step 6: Quality Control
- Viral titer determination
- Purity and sterility testing
- Genetic stability validation
What You'll Receive
| Deliverable | Description |
|---|---|
| ✓ Customized Vector Design | Fully optimized pseudotyped adenoviral construct |
| ✓ High-Titer Viral Stock | Ready-to-use purified viral particles |
| ✓ Tropism Validation Report | Cell-type specificity and efficiency data |
| ✓ QC Documentation | Titer, purity, sterility, sequencing |
| ✓ Technical Support | Ongoing consultation and optimization guidance |
Applications of Pseudotyping Adenoviral Vectors
By overriding natural tropism limits and evading pre-existing immunity, our engineered vectors unlock new potential across diverse biomedical fields:
-
Precision Oncolytic Virotherapy
Retarget vectors to specific tumor markers for enhanced tumor penetration and targeted lysis, while avoiding off-target liver toxicity. -
In Vivo Gene Therapy & Rare Diseases
Evade host immune clearance and deliver therapeutic transgenes directly to hard-to-reach tissues, such as the CNS, retina, and cardiac muscle. -
Ex Vivo Cell Engineering
Achieve near 100% transduction in historically difficult, CAR-negative cells like T cells, NK cells, and hematopoietic stem cells (HSCs). Ideal for safe, transient CRISPR/Cas9 delivery. -
Next-Generation Gene Vaccines
Specifically target Dendritic Cells (DCs) to maximize antigen presentation and provoke robust, long-lasting CD8+ T-cell immune responses.
Frequently Asked Questions (FAQ)
Q: Does pseudotyping or capsid modification affect the final viral titer or yield?
A: While spatial hindrance or assembly incompatibilities between capsid proteins of different serotypes can occasionally impact packaging efficiency, our virology team utilizes optimized linker design principles and highly productive packaging cell lines. We ensure the final delivered chimeric virus titer meets the rigorous demands of small animal in vivo studies (typically exceeding 10¹¹ vp/mL).
Q: Should I choose an Ad5/F35 pseudotyped vector or directly use an Ad35 vector?
A: Full-length Group B adenoviruses (like Ad35) generally produce yields 10 to 100 times lower than Ad5 in vitro. The Ad5/F35 chimeric vector perfectly marries the best of both worlds: the exceptionally high replication and packaging capacity of the Ad5 backbone, combined with the potent CD46-targeting ability of the Ad35 fiber. It is the most robust and cost-effective strategy available.
Q: Are pseudotyped adenoviral vectors suitable for delivering CRISPR/Cas9 systems?
A: Yes, they are highly ideal. Adenoviral vectors boast a massive cloning capacity (up to 8kb for first-generation, and over 30kb for helper-dependent vectors), which easily accommodates large Cas9 nucleases, multiple gRNA expression cassettes, and reporter genes. Combined with the pinpoint tissue specificity gained through pseudotyping, this platform delivers the gene-editing machinery directly to target tissues while heavily mitigating the risk of systemic off-target editing.
Q: What materials do I need to provide to initiate a project?
A: Simply provide a plasmid containing your gene of interest (or its NCBI accession number), and detail your specific targeting goals and final application (in vitro vs. in vivo). Our team handles everything else—from sequence synthesis and codon optimization to vector construction and final super-purification.
Partner with Creative Biolabs
Adenovirus-based gene delivery vectors can efficiently infect many different host cells, making them appealing tools for clinical gene therapy. As an experienced specialist in the biotechnology field, Creative Biolabs provides one-stop services to construct pseudotyping adenoviral vectors to transduce specialized cells with new tropism, which present antigens very effectively and enhance anti-vector immune responses. For more information, please feel free to contact us.
Reference
- Muravyeva A, Smirnikhina S. Strategies for modifying adenoviral vectors for gene therapy. International journal of molecular sciences, 2024, 25(22): 12461. https://doi.org/10.3390/ijms252212461 Distributed under Open Access license CC BY 4.0, without modification.
